Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma stocks lead the rally
Mon, 14 Nov 11:30 am

Indian stock market indices are trading strong over the last two hours of trade on the back of sustained buying activity witnessed across index heavyweights. Pharma and IT stocks witnessed maximum buying interest, while metal stocks witnessed maximum selling pressure.

The BSE-Sensex is up by 126 points, while the NSE-Nifty is up 37 points. BSE Mid Cap and BSE Small Cap indices are down by 0.1% and 0.2% respectively. The rupee is trading at 50.16 to the US dollar.

Aluminium stocks are trading mixed. Hindalco is trading in the green while National Aluminium Company Limited (NALCO) is trading in the red. NALCO has announced its results for the quarter ended September 2011. The company has reported a 9.1% YoY growth in sales and a 37.8% YoY decline in net profits. The decline in net profits was because of increase in raw material costs which saw an increase of 31.6% YoY. Operating profits saw a decline of 56.1% YoY on account of high expenditure. Operating margins declined from 23.5% in 2QFY11 to 9.5% in 2QFY12. Net profit margins declined by 6.5% YoY. For the half year ended September 2011, sales and net profits grew by 21.1% YoY and 1.6% YoY.

Finance stocks are trading mixed with Reliance Capital and SREI Infrastructure Finance trading weak. However, Power Finance Corporation (PFC) is trading in the green with significant gains. PFC has announced its results for the quarter ended September 2011. The company has reported a 17.5% YoY and 31% YoY growth in sales and net profits respectively. Net interest income rose by 18% YoY during 2QFY12 on the back of 26% YoY growth in advances. Bottomline declined by 40% YoY in 1HFY12 due to exchange rate losses and lower other income. Net interest margin (NIM) decreased to 3.9% in 1HFY12 from 4.1% in 1HFY11. Net NPA to advances increased to 0.19% at the end of 2QFY12, compared to 0.01% earlier. Capital adequacy ratio (CAR) stood at 18.2% at the end of 1HFY12.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Pharma stocks lead the rally". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.